Follow-up care over 12months of patients with prostate cancer in Spain

Vista sencilla de ítem
dc.contributor.authorBonfill, Xavier
dc.contributor.authorMartinez-Zapata, María José
dc.contributor.authorVernooij, Robin W.M.
dc.contributor.authorSánchez, María José
dc.contributor.authorMorales-Suárez-Varela, María
dc.contributor.authorEmparanza, José Ignacio
dc.contributor.authorFerrer, Montse
dc.contributor.authorPijoan, José Ignacio
dc.contributor.authorPalou, Joan
dc.contributor.authorMadrid, Eva
dc.contributor.authorAbraira, Victor
dc.contributor.authorZamora, Javier
dc.date.accessioned2022-11-30T02:46:30Z
dc.date.available2022-11-30T02:46:30Z
dc.date.issued2021
dc.description.abstractThe therapeutic approach is crucial to prostate cancer prognosis. We describe treatments and outcomes for a Spanish cohort of patients with prostate cancer during the first 12months after diagnosis and identify the factors that influenced the treatment they received. This multicenter prospective cohort study included patients with prostate cancer followed up for 12months after diagnosis. Treatment was stratified by factors such as hospital, age group (<70 and ≥70 years), and D’Amico cancer risk classification. The outcomes were Eastern Cooperative Oncology Group (ECOG) performance status, adverse events (AEs), and mortality. The patient characteristics associated with the different treatment modalities were analyzed using multivariate logistic regression. We included 470 men from 7 Spanish tertiary hospitals (mean (standard deviation) age 67.8 (7.6) years), 373 (79.4%) of which received treatment (alone or in combination) as follows: surgery (n=163; 34.7%); radiotherapy (RT) (n=149; 31.7%); and hormone therapy (HT) (n=142; 30.2%). The remaining patients (n=97) were allocated to no treatment, that is, watchful waiting (14.0%) or active surveillance (5.7%). HT was the most frequently administered treatment during follow-up and RT plus HT was the most common therapeutic combination. Surgery was more frequent in patients aged <70, with lower histologic tumor grades, Gleason scores <7, and lower prostate-specific antigen levels; while RT was more frequent in patients aged ≥70 with histologic tumor grade 4, and higher ECOG scores. HT was more frequent in patients aged ≥70, with histologic tumor grades 3 to 4, Gleason score ≥8, ECOG ≥1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12months (P<.001); 230 (48.9%) patients had at least 1 AE, and 12 (2.6%) patients died. Surgery or RT were the main curative options. A fifth of the patients received no treatment. Palliative HT was more frequently administered to older patients with higher tumor grades and higher Gleason scores. Close to half of the patients experienced an AE related to their treatment.en_ES
dc.facultadFacultad de Medicinaen_ES
dc.file.nameMadrid_Follo2021.pdf
dc.identifier.citationBonfill X, Martinez-Zapata MJ, Vernooij RW, Sánchez MJ, Morales-Suárez-Varela M, Emparanza JI, Ferrer M, Pijoan JI, Palou J, Madrid E, Abraira V, Zamora J. Follow-up care over 12months of patients with prostate cancer in Spain: a multicenter prospective cohort study. Medicine 2021;100:47(e27801).en_ES
dc.identifier.doihttp://dx.doi.org/10.1097/MD.0000000000027801
dc.identifier.urihttp://repositoriobibliotecas.uv.cl/handle/uvscl/7398
dc.languageen
dc.publisherWolters Kluwer Health
dc.rightsThis is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.sourceMedicine
dc.subjectHORMONE THERAPYen_ES
dc.subjectMULTICENTER STUDYen_ES
dc.subjectMULTIVARIATE ANALYSISen_ES
dc.subjectPROSTATE CANCERen_ES
dc.subjectPROSTATIC NEOPLASMSen_ES
dc.subjectRADIOTHERAPYen_ES
dc.subjectSURGERYen_ES
dc.titleFollow-up care over 12months of patients with prostate cancer in Spain
dc.typeArticulo
uv.departamentoCentro Interdisciplinario de Estudios en Salud (CIESAL)

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Madrid_Follo2021.pdf
Tamaño:
367.85 KB
Formato:
Adobe Portable Document Format
Descargar

Colecciones

Artículos investigadores UV